Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient–Level Analysis of Multiple Randomized Trials (SEAL)

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient–Level Analysis of Multiple Randomized Trials (SEAL)

Purpose Overall survival (OS) is the definitive and best-established primary efficacy end point to evaluate diffuse large B-cell lymphoma (DLBCL) therapies, but it requires prolonged follow-up. An earlier end point assessed post-treatment would expedite clinical trial conduct and accelerate patient...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Qian Shi, Norbert Schmitz, Fang‐Shu Ou, Jesse G. Dixon, David Cunningham, Michael Pfreundschuh, John F. Seymour, Ulrich Jaeger, Thomas M. Habermann, Corinne Haïoun, Hervé Tilly, Hervé Ghesquières, Francesco Merli, Marita Ziepert, Raoul Herbrecht, Jocelyne Flament, Tommy Fu, Bertrand Coiffier, Christopher R. Flowers
Aineistotyyppi: Artigo
Kieli:englanti
Julkaistu: 2018
Linkit:https://doi.org/10.1200/jco.2018.77.9124
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Internet

https://doi.org/10.1200/jco.2018.77.9124

Samankaltaisia teoksia